drugset / Trial / NCT06326814
A Study to Test if SAR443809 is Tolerated and Safe When Taken as a Single Dose in Healthy Adults
RandomizedSequentialDouble-blindTreatment
Summary
Primary objective * The tolerability and safety of SAR443809 Secondary * The PK parameters of SAR443809 * The PD activity of SAR443809 * The immunogenicity of SAR443809
Timeline
- Start
- 2021-10-11
- Primary completion
- 2023-05-05
- Completion
- 2023-05-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SAR443809 | Monoclonal antibody | — | Intravenous |